let me sell you on this stock.

Hereditary haemochromatois (hhc) is believed to be the most common genetic disorder in the USA, affecting about 2,000,000 people yearly in that market.The non-invasive nature of the FerriScan test means that clinicians can now safely and accurately measure the amount of iron in a patient's liver on a regular basis.

It can also measure liver iron content for Thalassemia patients and potentially for Hepatitis C sufferers undergoing drug therapy.

At US$450 a scan x 2,000,000 = $900,000 000 per year in revenue.That is just in the USA.This is why l am fired up about this stock.Lets say they only get 10% of this potential 2,000,000 people that is still $90,000,000 US in revenue.

THIS STOCK IS CHEAP! VERY CHEAP.

Please show me a stock that has not taken off yet with such huge potential.